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11 Abstract
12 Purpose Endotracheal intubation is the gold standard for
13 securing the airway before surgery. Nevertheless, this
14 procedure can produce an activation of the sympathetic
15 nervous system and result in a hemodynamic response
16 which, in high-risk patients, may lead to cardiovascular
17 instability and myocardial ischemia. The aim of this review
18 was to evaluate whether gabapentin can attenuate this
19 response and whether such an attenuation could translate
20 into reduced myocardial ischemia and mortality.
21 Source We searched MEDLINE, EMBASETM, CINAHL,
22 AMED, and unpublished clinical trial databases for
23 randomized-controlled trials that compared gabapentin
24 with control, fentanyl, clonidine, or beta blockers for
25 attenuating the hemodynamic response to intubation.
26 Primary outcomes were mortality, myocardial infarction,
27 and myocardial ischemia. Secondary outcomes were
28 hemodynamic changes following intubation.
29 Principal findings We included 29 randomized trials with
30 only two studies at low risk of bias. No data were provided
31 for the primary outcomes and no studies included high-risk
32 patients. The use of gabapentin resulted in attenuation in
33 the rise in mean arterial blood pressure [mean difference
34 (MD), -12 mmHg; 95% conﬁdence interval (CI), -17 to
35 -8] and heart rate (MD, -8 beatsmin
-1; 95% CI, -11 to
36 -5) one minute after intubation. Gabapentin also reduced
37 the risk of hypertension or tachycardia requiring treatment
38 (risk ratio, 0.15; 95% CI, 0.05 to 0.48). Data were limited
39on adverse hemodynamic events such as bradycardia and
40hypotension.
41Conclusion It remains unknown whether gabapentin
42improves clinically relevant outcomes such as death and
43myocardial infarction since studies failed to report on
44these. Nevertheless, gabapentin attenuated increases in
45heart rate and blood pressure following intubation when
46compared with the control group. Even so, the studies
47included in this review were at potential risk of bias.
48Moreover, they did not include high-risk patients or report
49adverse hemodynamic outcomes. Future studies are
50required to address these limitations.
51
52Re´sume´
53Objectif L’intubation endotrache´ale constitue l’e´talon or
54de la prise en charge des voies ae´riennes avant une
55chirurgie. Toutefois, cette intervention peut entraıˆner une
56activation du syste`me nerveux sympathique et provoquer
57une re´ponse he´modynamique qui, chez les patients courant
58un risque e´leve´, pourrait mener a` une instabilite´
59cardiovasculaire et une ische´mie myocardique. L’objectif
60de ce compte rendu e´tait d’examiner si la gabapentine
61pouvait atte´nuer cette re´ponse et si une telle atte´nuation
62pouvait se traduire en une re´duction de l’ische´mie
63myocardique et de la mortalite´.
64Source Nous avons effectue´ des recherches dans les bases
65de donne´es MEDLINE
, EMBASETM, CINAHL, AMED,
66ainsi que dans les bases de donne´es d’e´tudes cliniques non
67publie´es aﬁn d’en extraire les e´tudes randomise´es
68controˆle´es comparant la capacite´ de la gabapentine par
69rapport a` un groupe te´moin, au fentanyl, a` la clonidine ou
70a` des beˆta-bloquants, a` atte´nuer la re´ponse
71he´modynamique a` l’intubation. La mortalite´, l’infarctus
72du myocarde et l’ische´mie myocardique e´taient les
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73 principaux crite`res d’e´valuation. Les crite`res d’e´valuation
74 secondaires e´taient les changements he´modynamiques
75 suite a` l’intubation.
76 Constatations principales Nous avons inclus 29 e´tudes
77 randomise´es, dont deux seulement afﬁchaient un risque
78 faible de biais. Aucune donne´e n’e´tait fournie concernant
79 les crite`res d’e´valuation principaux et aucune e´tude
80 n’incluait de patients a` risque e´leve´. L’utilisation de la
81 gabapentine a entraıˆne´ une atte´nuation de l’augmentation
82 de la tension arte´rielle moyenne [diffe´rence moyenne
83 (DM), -12 mmHg; intervalle de conﬁance (IC) 95 %, -17
84 a` -8] et de la fre´quence cardiaque (DM, -8
85 battementsmin
-1; IC 95 %, -11 a` -5) une minute apre`s
86 l’intubation. La gabapentine a e´galement re´duit le risque
87 d’hypertension ou de tachycardie ne´cessitant un traitement
88 (risque relatif, 0,15; IC 95 %, 0,05 a` 0,48). Les donne´es
89 concernant les complications he´modynamiques telles que
90 la bradycardie et l’hypotension e´taient limite´es.
91 Conclusion Nous ne savons pas si la gabapentine
92 ame´liore des re´sultats pertinents d’un point de vue
93 clinique tels que le de´ce`s ou l’infarctus du myocarde,
94 e´tant donne´ que les e´tudes examine´es ne faisaient pas
95 mention de ces donne´es. Toutefois, la gabapentine a
96 atte´nue´ les augmentations de fre´quence cardiaque et de
97 tension arte´rielle apre`s l’intubation comparativement au
98 groupe te´moin. Ceci e´tant dit, les e´tudes incluses dans ce
99 compte rendu couraient un risque potentiel de biais. De
100 plus, elles n’incluaient pas de patients a` risque e´leve´ ni ne
101 rapportaient de complications he´modynamiques. Des
102 e´tudes supple´mentaires sont ne´cessaires pour pallier ces
103 limitations.
104
105
106 Endotracheal intubation is the gold standard for securing
107 the airway before surgery. Nevertheless, this procedure
108 may cause activation of the sympathetic nervous system
109 and release of catecholamines, resulting in a hemodynamic
110 response that precipitates an increase in heart rate (HR) and
111 blood pressure. This response does not cause problems in
112 most patients; however, in high-risk patient groups, such as
113 those with preexisting cardiovascular disease, such
114 responses may increase the risk of myocardial ischemia,
115 myocardial infarction, and mortality.
1 As the number of
116 elderly patients undergoing surgery increases, adverse
117 cardiovascular responses to endotracheal intubation may
118 therefore present an increasing problem in the
119 perioperative period. Many agents have been used to
120 attenuate this response, but few studies report clinically
121 relevant outcomes such as morbidity or mortality.
2
122 Increases in hemodynamic and sympathetic responses
123 around the perioperative period may increase myocardial
124demand and ensuing adverse cardiac outcomes.
3 Triggers
125for these reactions include intubation, extubation, surgery,
126and pain. The likelihood of such adverse effects led to the
127conduct of randomized-controlled trials evaluating
128cardioprotective agents, such as beta blockers and
129clonidine, in reducing perioperative myocardial events.
130The Perioperative Ischemic Evaluation (POISE)
4 study
131found that perioperative metoprolol reduced myocardial
132infarction; however, the study did not focus specifically on
133the specified time period of intubation and there was an
134increase in overall mortality and stroke. Clonidine has also
135shown initial promise,
5 although results of the recent
136POISE 2 study showed no reduction in cardiac events or
137mortality and an increase in clinically significant
138hypotension and non-fatal cardiac arrest.
6 Therefore, the
139search for alternative agents that do not produce such
140adverse effects is a clinically important issue for high-risk
141patients undergoing surgery.
142Gabapentin has proven efficacy in reducing
143postoperative pain, lowering opioid consumption, and
144reducing postoperative nausea and vomiting.
7 A recent
145meta-analysis has also identified the benefits of gabapentin
146with regard to preoperative anxiety and chronic pain at the
147expense of an increase in sedation.
8 Over the last decade,
148randomized-controlled trials have been published
149indicating that gabapentin may also be useful in
150attenuating the hemodynamic response to intubation.
9
151Nevertheless, these studies included a small number of
152participants and were not conducted in multiple clinical
153populations. Moreover, it is as yet unknown how
154gabapentin compares with other agents and whether such
155reductions in hemodynamic variables could translate into
156reductions in clinically relevant postoperative outcomes.
157Due to the disappointing results from clinical trials of
158clonidine and beta blockers in reducing perioperative
159myocardial events,
10 this review aimed to evaluate
160whether gabapentin can attenuate the hemodynamic
161response to intubation and whether this can translate into
162reductions in myocardial ischemia and myocardial
163infarction and ultimately reduce postoperative mortality.
164Methods
165Search strategy
166In conducting this review, we adhered to the standards of
167reporting in the Preferred Reporting Items for Systematic
168Reviews and Meta-Analyses (PRISMA) checklist.
11 We
169prospectively registered the review on the PROSPERO
170website using the registration number CRD42015027012.
171A deviation from the original protocol was the addition of
B. Doleman et al.
123
Journal : Large 12630 Dispatch : 9-5-2016 Pages : 17
Article No. : 668
h LE h TYPESET
MS Code : CAAN-D-16-00002 h CP h DISK4 4
A
u
th
o
r
 P
r
o
o
f
U
N
C
O
R
R
E
C
T
E
D
P
R
O
O
F
172 intravenous fentanyl as a comparison due to its use as the
173 standard agent at induction of anesthesia. We searched the
174 following databases: MEDLINE
 (1946-September 2015)
175 (Appendix), EMBASE
TM (1974- September 2015),
176 CINAHL (1981- September 2015), AMED (1985-
177 September 2015), and CENTRAL (until September
178 2015). We searched for studies using the keywords in the
179 title and abstract, gabapentin, Neurontin, and intubation.
180 The MeSH terms intubation and intratracheal were
181 exploded and combined with the above terms. We also
182 searched for unpublished studies from Clinicaltrials.gov,
183 the ISRCTN registry, and the WHO international clinical
184 trials registry. Furthermore, we searched the reference lists
185 of the identified studies and used Google Scholar to
186 identify studies that had cited those included. We contacted
187 the authors if further information was required.
188 Inclusion criteria
189 We included randomized-controlled trials that compared
190 gabapentin with either placebo or no treatment in patients
191 undergoing endotracheal intubation before surgery. We
192 also included studies comparing the administration of
193 gabapentin with fentanyl, clonidine, or beta blockers. We
194 included adult patients only ([ 15 yr old) undergoing any
195 type of surgery. There were no restrictions based on
196 publication status or language. When necessary, we used
197 Google Translate to translate papers in non-English-
198 language papers. Two study authors (B.D. and M.S.)
199 independently evaluated the identified studies against the
200 inclusion criteria, and agreement was reached by
201 consensus.
202 Outcomes
203 The primary outcomes were mortality, myocardial
204 ischemia, and myocardial infarction. We defined
205 mortality as early (\ 48 hr) and late (30 days). If studies
206 reported more than one time point, we included the earliest
207 time in the analysis. Myocardial ischemia was defined as
208 ST segment depression from continuous electrocardiogram
209 (ECG) recordings. Myocardial infarction was defined as
210 two of the following three criteria: chest pain, ECG
211 ischemic changes, and/or[ 25% rise in high-sensitivity
212 troponin measurements. Secondary outcomes included HR,
213 mean arterial blood pressure, systolic blood pressure
214 (SBP), and diastolic blood pressure (DBP) measured at
215 one, five, and ten minutes after intubation. We also
216 measured the following outcomes: arrhythmias, plasma
217 catecholamine concentrations, hypotension (requiring
218 treatment), bradycardia (requiring treatment), and
219 tachycardia or hypertension (requiring treatment).
220Data extraction and risk of bias
221Two study authors (B.D. and M.S.) extracted the following
222information onto an electronic database: study name, year
223of publication, mean age of participants, percentage of
224female participants, sample size, intervention, comparator,
225country, perioperative medication, induction agents,
226maintenance agents, laryngoscope and endotracheal tube
227used, participant population, type of surgery, and duration
228of intubation. The same two authors assessed risk of bias
229using the Cochrane tool for assessing risk of bias,
12 and
230agreement was reached by consensus. We assessed the
231following domains: randomization, allocation
232concealment, blinding, attrition bias, selective outcome
233reporting, and other sources of bias. These domains were
234assessed as low risk, unclear risk, and high risk and
235presented in a risk of bias table.
236Statistical analysis
237We present continuous outcomes using mean difference
238(MD) and dichotomous outcomes using risk ratios (RR).
239The precision of outcomes is presented with 95%
240confidence intervals (95% CI). We regarded a 10%
241relative risk difference in dichotomous outcomes, a 10
242mmHg MD in blood pressure, and 5 beatsmin
-1 MD in
243HR as clinically significant. We were unaware of any data
244directly linking changes in hemodynamic variables and risk
245of myocardial events, and therefore, these values for
246clinical significance were not empirically derived. Where
247data were not presented, authors were contacted to provide
248further information. If no response was received, the results
249were extracted from published graphs. If standard
250deviations were not published, we estimated these from
251other studies in the meta-analysis.
13 We used the Grading
252of Recommendations, Assessment, Development and
253Evaluations (GRADE) Working Group criteria to assess
254the quality of evidence for each outcome.
14 The evidence is
255downgraded owing to any concerns regarding the
256indirectness of evidence, lack of precision in effect
257estimates, potential publication bias, unexplained
258heterogeneity, and risk of bias in results. This is a
259qualitative downgrading from high quality to moderate,
260low, or very low quality dependent on the concerns cited
261above. We made no statistical adjustment of results.
262Data were aggregated using a random effects model due
263to substantial clinical heterogeneity in the gabapentin dose
264and baseline hemodynamic variables of the participants.
265Statistical heterogeneity is presented using the I
2 statistic
266with a corresponding P value derived from the Chi square
267statistic. We regarded I
2 of[50% or P\0.10 as evidence
268of statistical heterogeneity. When more than ten studies
269were included in the meta-analysis, we assessed small
Gabapentin for intubation
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270 study effects, including possible publication bias, using
271 Egger’s linear regression test.
15 We regarded a one-tailed P
272 \ 0.10 as evidence of small study effects.
273 Investigation of heterogeneity was conducted using a
274 method of moments random-effects meta-regression.
16
275 Covariates included the dose of gabapentin and baseline
276 hemodynamic variables of the participants. We calculated
277 the baseline hemodynamic measurements by taking the
278 mean measurement from the gabapentin and control groups
279 recorded before induction of anesthesia (where reported).
280 We assessed residuals for normality, linearity, and
281 heteroscedasticity. We used Cook’s distance to assess the
282 model for influential cases and the variance inflation factor
283 for evidence of multicollinearity. We present results as the
284 R
2 analogue with a corresponding P value for the model
285 (significance level P \ 0.10). We conducted sensitivity
286 analysis by including studies at low risk of bias (defined as
287 low risk for randomization, allocation concealment,
288 blinding and attrition bias, and no high-risk domains),
289 excluding studies with estimated standard deviations, and
290 using ‘‘Remove-One’’ analysis.
291 We conducted trial sequential analysis for each outcome
292 when gabapentin was compared with control. This analysis
293 allows for control of type I errors, which may occur early
294 on in the systematic review process (false discovery rate).
295 This is analogous to the problems of multiple statistical
296 testing in primary studies. Monitoring boundaries can be
297 constructed so that, early in the evidence accrual, a greater
298 Z score is required to reach statistical significance. As each
299 study is published, a cumulative Z score is calculated, and
300 if this crosses the monitoring boundary, it can be assumed
301 that statistical significance is adjusted for multiple
302comparisons. We constructed O’Brien-Fleming
303monitoring boundaries for benefit assuming an alpha
304level of 0.05 and a 1-beta of 0.80. In addition, we
305calculated the required number of included participants to
306provide a definitive result (information size) in order to
307reduce type II errors.
17 This part of the analysis is
308analogous to a sample size calculation in primary
309research studies, which also makes allowances for the
310statistical heterogeneity of results and the uncertainty that
311surrounds these. We used previously stated clinically
312relevant MDs for continuous outcomes (10 mmHg or 5
313beatsmin
-1) and 20% or 50% relative risk reductions for
314dichotomous outcomes. We used the included studies in
315each analysis to estimate the diversity (D
2 with a calculated
316heterogeneity correction) and variance. We conducted
317sensitivity analyses around these estimates. All analyses
318were performed using Review Manager 5.3,
18
319Comprehensive Meta-Analysis V3.3,
19 and Trial
320Sequential Analysis 0.9 beta software from the
321Copenhagen Trial Unit (http://www.ctu.dk/tsa).
322Results
323Description of included studies
324We screened 95 studies identified from searching
325electronic databases and handsearching reference lists
326(Fig. 1) and included 29 studies in the meta-analysis
327(Table).
20-48 All the included studies enrolled American
328Society of Anesthesiologists physical status I or II patients
329with no preexisting cardiac risk factors, and there were no
Fig. 1 PRISMA flowchart for
included studies
B. Doleman et al.
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330studies involving patients at high risk for adverse cardiac
331outcomes. One study included patients with hypertensive
332disease,
26 and one study used invasive blood pressure
333monitoring to record hemodynamic variables.
22 Only one
334study provided details of the equipment used to measure
335noninvasive blood pressure.
33 There was clinical
336heterogeneity in the doses of gabapentin used, with doses
337ranging from 300-1,200 mg. Most studies administered
338gabapentin from one to two hours before surgery. In terms
339of risk of bias assessments, allocation concealment was
340rarely adequately reported. The risk of bias for each
341included study is presented in Fig. 2. Only two studies
342were at low risk of bias.
35,41 None of the hemodynamic
343values measured declined below post-induction values
344following intubation.
345Gabapentin vs control
346Primary outcomes
347None of the included studies reported mortality or
348myocardial infarction or measured them as outcomes.
349Nine studies
21,22,25,26,33,35,38,39,41 reported myocardial
350ischemia. There were no events in either group in any of
351the included studies. All studies reporting myocardial
352ischemia derived data from ST changes on ECG recordings
353during the intraoperative period.
354Secondary outcomes
355Mean arterial blood pressure Gabapentin attenuated the
356rise in mean arterial pressure (MAP) at one minute when
357compared with the control group (MD, -12 mmHg; 95%
358CI, -17 to -8; low quality) (Fig. 3). At five minutes, the
359analysis included 21 studies
21-24,26,28-30,32-39,41,43-45,47 with
3601,350 participants where the aggregated effect estimate
361showed an attenuated rise with gabapentin (MD -9
362mmHg; 95% CI, -13 to -5; low quality). At ten
363minutes, the analysis included 18
364studies
21-23,26,28,30,32-39,41,43,44,47 with 1,244 participants
365where the aggregated effect estimate showed an
366attenuated rise with gabapentin (MD, -8 mmHg; 95%
367CI, -11 to -5; low quality).
368There was evidence of statistical heterogeneity for all
369time points (I
2 = 82-93%; P \ 0.001). There was no
370evidence of small study effects at one or ten minutes (P =
3710.14 and P = 0.36, respectively). There was evidence of
372small study effects at five minutes (P = 0.001); however,
373the studies were missing from the left of the plot,
374suggesting a bias against gabapentin for this outcome. On
375meta-regression analysis, increasing the gabapentin dose or
376baseline MAP did not significantly predict gabapentin
377effect at any time point. Trial sequential analysis showedT
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378 that gabapentin crossed the O’Brien-Fleming monitoring
379 boundary for benefit for each time point. In addition, the
380 required information size was reached for one, five, and ten
381 minutes (909, 824, and 432 participants, respectively).
382Heart rate Gabapentin attenuated the rise in HR at one
383minute after intubation when compared with the control
384group (MD, -8 beatsmin
-1; 95% CI, -11 to -5;
385moderate quality). At five minutes, the analysis included
38625 studies
20-39,41,43-45,47 with 1,564 participants where the
387aggregated effect estimate showed an attenuated rise with
388gabapentin (MD, -6 beatsmin
-1; 95% CI, -8 to -4;
389moderate quality). At ten minutes, the analysis included 22
390studies
20-23,25-28,30-39,41,43,44,47 with 1,458 participants
391where the aggregated effect estimate showed an
392attenuated rise with gabapentin (MD, -5 beatsmin
-1;
39395% CI, -7 to -3; moderate quality) (Fig. 4).
394There was evidence of statistical heterogeneity at all
395time points (I
2 = 46-76%; P\0.01). There was evidence of
396small study effects at one and five minutes (P = 0.05 and P
397= 0.004, respectively); however, the missing studies were
398to the left of the mean, suggesting a bias against
399gabapentin. On meta-regression analysis, an increase in
400the gabapentin dose predicted greater attenuation in HR at
401one minute (R
2 = 35%; P = 0.006), five minutes (R2 = 38%;
402P = 0.02), and ten minutes (R
2 = 52%; P = 0.004). Baseline
403HR was not a significant predictor at any time point. Trial
404sequential analysis showed that gabapentin crossed the
405O’Brien-Fleming boundary for benefit at all time points. In
406addition, the results for five and ten minutes reached the
407required information size (1,339 and 784 participants,
408respectively). Nevertheless, the results for one minute
409failed to reach the required information size (2,022
410participants).
411Systolic blood pressure At one minute after intubation,
412the analysis included 15
413studies
20,21,24,27,28,31,32,34,36,37,43-45,47,48 with 928
414participants where the aggregated effect estimate showed
415gabapentin attenuated the rise in SBP when compared with
416the control group (MD, -16 mmHg; 95% CI, -22 to -9;
417low quality). At five minutes, the analysis included 15
418studies
20,21,24,27,28,30-32,34,36,37,43-45,47 with 921 participants
419where the aggregated effect estimate showed an attenuated
420rise with gabapentin (MD, -10 mmHg; 95% CI, -16 to
421-4; low quality). At ten minutes, the analysis included 13
422studies
20,21,27,28,30-32,34,36,37,43,44,47 with 855 participants
423where the aggregated effect estimate showed an attenuated
424rise with gabapentin (MD, -9 mmHg; 95% CI, -16 to -2;
425low quality).
426There was evidence of substantial statistical
427heterogeneity at all time points (I
2 = 89-94%; P \
4280.001). There was no evidence of small study effects at
429one (P = 0.27), five (P = 0.43), or ten minutes (P = 0.30).
430On meta-regression analysis, gabapentin dose and baseline
431SBP did not significantly predict gabapentin effect. Trial
432sequential analysis showed that gabapentin crossed the
433O’Brien-Fleming boundary for benefit at one and five
Fig. 2 Risk of bias for included studies. Green indicates low risk,
yellow indicates unclear risk, and red indicates high risk
AQ1
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434 minutes. Nevertheless, the result for ten minutes did not
435 cross the boundary for benefit. In addition, results at one,
436 five, and ten minutes did not reach the required information
437 size (1,507, 1,163, and 1,654 participants, respectively).
438 Diastolic blood pressure At one minute after intubation,
439 the analysis included 14
440 studies
20,21,24,27,28,31,32,34,36,37,43,44,47,48 with 892
441 participants where the aggregated effect estimate showed
442 an attenuated rise in DBP with gabapentin when compared
443 with control (MD, -11 mmHg; 95% CI, -15 to -7; low
444 quality). At five minutes, the analysis included 14
445 studies
20,21,24,27,28,30-32,34,36,37,43,44,47 with 885 participants
446 where the aggregated effect estimate showed an attenuated
447rise with gabapentin (MD -7 mmHg; 95% CI, -11 to -4;
448low quality). At ten minutes, the analysis included 13
449studies
20,21,27,28,30-32,34,36,37,43,44,47 with 855 participants
450where the aggregated effect estimate showed an attenuated
451rise with gabapentin (MD, -6 mmHg; 95% CI -10 to -2;
452low quality).
453There was evidence of substantial statistical
454heterogeneity at all time points (I
2 = 79-89%; P \
4550.001). There was no evidence of small study effects at
456one (P = 0.32), five (P = 0.24), or ten minutes (P = 0.30).
457On meta-regression analysis, gabapentin dose and baseline
458DBP did not significantly predict gabapentin effect at any
459time point. Trial sequential analysis showed that the results
460for gabapentin crossed the O’Brien-Fleming boundary for
Fig. 3 Forest plot of gabapentin effects on mean arterial pressure at one minute
Fig. 4 Forest plot of gabapentin effects on heart rate at one minute
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461 benefit for all time points. In addition, the required
462 information size was reached for one, five, and ten
463 minutes (647, 446, and 540 participants, respectively).
464 Other secondary outcomes
465 Eight studies
21,22,25,26,33,35,38,41 reported arrhythmias as an
466 outcome; there were no events in any of the included
467 studies. In terms of catecholamine secretion, one study
22
468 concluded that gabapentin resulted in lower secretion of
469 adrenaline one minute after intubation when compared
470 with placebo (MD, -5 pgmL
-1; 95% CI, -9 to -1).
471 Nevertheless, the secretion of noradrenaline
22 was higher
472 when compared with placebo one minute after intubation
473 (MD, 65 pgmL
-1; 95% CI, 47 to 83).
474 Gabapentin use reduced the incidence of hypertension or
475 tachycardia requiring treatment in five studies (RR, 0.15;
476 95% CI, 0.05 to 0.48; moderate quality). Trial sequential
477 analysis showed that gabapentin crossed the boundary for
478 benefit, although it did not reach the required information
479 size (558 participants). Definitions for this outcome were as
480 follows; SBP [ 200 mmHg or [ 30% increase from
481 baseline for more than 60 sec;
22,38 HR[130 beatsmin-1,
482 SBP[ 200 mmHg or[ 30% increase from baseline for
483 more than 60 sec;
26 MAP or HR[20% of baseline;29 MAP
484 [ 110 mmHg.
40
485 One study
26 conducted in hypertensive patients reported
486 any incidences of hypotension requiring treatment (SBP\
487 90 mmHg or[ 30% from baseline lasting more than 60
488 sec); there were no significant differences between the
489 groups (RR, 2.40; 95% CI, 0.74 to 7.79). One study
31
490 reported any incidence of bradycardia requiring treatment
491 (HR\40 beatsmin
-1). There was no significant difference
492 in bradycardia with gabapentin (RR, 3.00; 95% CI, 0.13 to
493 69.87).
494 Gabapentin vs fentanyl, clonidine, or beta blockers
495 When compared with clonidine, the only significant
496 difference in hemodynamic variables was a higher HR at
497 ten minutes in the gabapentin group when compared with
498 the clonidine group
37,39,42-44 (MD, 5 beatsmin-1; 95% CI,
499 3 to 7; moderate quality). One study
45 compared
500 gabapentin with a beta blocker (esmolol). The only
501 difference in hemodynamic variables was a higher HR at
502 one minute in the gabapentin group when compared with
503 the esmolol group (MD, 13 beatsmin
-1; 95% CI, 4 to 21).
504 The incidence of bradycardia was not significantly
505 different when gabapentin was compared with clonidine
506 (RR, 0.49; 95% CI, 0.07 to 3.60) or esmolol (RR, 0.33;
507 95% CI, 0.01 to 7.68).
508 One study compared gabapentin with intravenous
509 fentanyl.
41 Intravenous fentanyl resulted in greater
510attenuation of HR at one (MD, 14 beatsmin
-1; 95% CI,
5118 to 20), five (MD, 12 beatsmin
-1; 95% CI, 7 to 17), and
512ten minutes (MD, 10 beatsmin
-1; 95% CI, 5 to 15).
513Furthermore, intravenous fentanyl resulted in greater
514attenuation of MAP at one minute (MD, 13 mmHg; 95%
515CI, 8 to 18).
516Sensitivity analysis
517Only two of the included studies were at low risk of
518bias,
35,41 which resulted in no significant reductions for
519many outcomes. Excluding studies with estimated standard
520deviations did not significantly affect results. ‘‘Remove-
521One’’ sensitivity analysis showed that there were no
522influential studies in any of the analyses.
523Discussion
524There are several limitations with the results of this review.
525We were unable to provide any results for the primary
526outcomes because the inclusion of low-risk patients
527resulted in either zero incidences of these events or lack
528of reporting of these outcomes within the included studies.
529Secondly, as previously discussed, there is limited
530evidence with regard to clinically important adverse
531events such as hypotension and bradycardia. Many
532studies were at potential risk of bias, particularly for
533allocation concealment, which may bias the results from
534this review.
49 Indeed, only two studies35,41 included in the
535review were deemed to be at low risk of bias for most
536domains, which limited the quality of the evidence.
14 In
537addition to these issues with internal validity, many of the
538studies included in the review were conducted in the
539Middle East and Asia, and therefore, the applicability of
540our results to North American and European populations is
541unclear.
542With regard to outcome measurements, very few of the
543included studies provided details of the equipment used to
544obtain noninvasive blood pressure measurements. As
545values from oscillometric methods are algorithmically
546derived, these may vary between devices, which may
547introduce heterogeneity into our results. Also, this lack of
548information meant that it was problematic to evaluate
549whether such devices are valid, precise, and accurate. As
550the majority of the included studies measured blood
551pressure at discrete time points, important hypotensive or
552hypertensive episodes may have been missed, as such
553discrete measurements may not reflect the average values
554occurring between such measurements. Finally, it is
555unclear how gabapentin compares with other standard
556agents such as lidocaine. Importantly, when gabapentin
557was directly compared with a standard agent such as
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558 intravenous fentanyl, gabapentin was inferior for many
559 hemodynamic outcomes.
560 Despite the limitations of the review, we found that
561 gabapentin resulted in significant attenuation of mean
562 arterial blood pressure, HR, SBP, and DBP when compared
563 with control (moderate- to low-quality evidence). Most of
564 these results crossed the monitoring boundaries for benefit
565 and reached the required information sizes for a definitive
566 answer on trial sequential analysis, reducing type I and II
567 errors in our analysis. In addition, gabapentin resulted in a
568 significant reduction in the proportion of patients requiring
569 treatment for hypertension or tachycardia. Following
570 intubation, one study found that gabapentin reduced
571 circulating levels of adrenaline and increased
572 noradrenaline. Although data were limited, gabapentin
573 appears comparable with clonidine and beta blockers in
574 terms of its hemodynamic effects following intubation.
575 Increases in gabapentin dosages were associated with
576 greater attenuation of HR responses on meta-regression
577 analysis. Although many of these outcomes reached our
578 predefined clinical thresholds, caution is advised as these
579 were not empirically derived.
580 The hemodynamic response to intubation involves a
581 stress response, which leads to increases in catecholamine
582 levels and subsequent increases in HR and blood
583 pressure.
50 In high-risk patients, such increases can lead
584 to myocardial ischemia and therefore myocardial
585 infarction.
1,51,52 Many agents have been used to
586 attenuate the hemodynamic response to intubation and
587 thus aim to reduce myocardial ischemia.
2 Although agents
588 such as clonidine
53 and beta blockers have shown promise
589 in reducing perioperative cardiac events, the large
590 randomized-controlled POISE studies showed an
591 increase in mortality and stroke with perioperative beta
592 blocker therapy
4 and increases in clinically important
593 hypotension and non-fatal cardiac arrest with clonidine.
6
594 Therefore, the search continues for effective agents that
595 can reduce perioperative myocardial events in high-risk
596 patients without increasing such adverse events as
597 hypotension and bradycardia and therefore all-cause
598 mortality. Although such perioperative events as
599 intubation, extubation, surgery, and pain can contribute
600 to increasing myocardial demand,
3 our review focused
601 only on the brief hemodynamic response following
602 intubation. Therefore, we advise caution in extrapolating
603 these results with any direct link with longer-term adverse
604 cardiac events in the perioperative period, such as those
605 studied in POISE. Despite this limitation, gabapentin is
606 known to reduce postoperative pain,
8 attenuate the
607 hemodynamic response to intubation, and reduce
608 catecholamine and cortisol responses postoperatively;
54
609 therefore, longer-term effects on reducing myocardial
610 demand cannot be ruled out.
611Gabapentin has proven efficacy as a perioperative
612analgesic with reductions in pain scores and lower opioid
613consumption in various types of surgery.
8 Other beneficial
614effects include reductions in preoperative anxiety,
615vomiting, and pruritus, with some evidence of reductions
616in chronic post-surgical pain at the expense of increased
617sedation.
8,55 Interestingly, these trials provide the only
618evidence of the effects of gabapentin in high-risk patients.
619Within these postoperative pain trials, the results of studies
620with cardiothoracic surgery patients
8,56-58 (which included
621high-risk cardiac patients) suggest a reduction in
622postoperative arrhythmia with the use of gabapentin (RR,
6230.55; 95% CI, 0.28 to 1.08).
624Our review suggests that gabapentin may also be an
625effective agent for attenuation of the hemodynamic
626response to intubation. We found only one study
627suggesting that this might be mediated by reductions in
628adrenaline when compared with control.
22 Previous in vitro
629research has suggested that gabapentin may inhibit the
630release of catecholamines from adrenal chromaffin cells,
59
631which may confirm this as a possible mechanism of action.
632Furthermore, a recent randomized-controlled trial has
633shown that preoperative gabapentin can reduce
634postoperative catecholamine (both adrenaline and
635noradrenaline) and cortisol concentrations in women
636undergoing hysterectomy.
54 Nevertheless, the magnitude
637of difference in adrenaline between the groups in our
638review was around 8%, which may be regarded as
639clinically small. Another potential mechanism may relate
640to calcium channel inhibition. As calcium channel blockers
641can attenuate the hemodynamic response and share a target
642mechanism with gabapentin, this may produce similar
643effects in a clinical population.
60
644Our meta-regression analysis found that a gabapentin
645dose was associated with greater attenuation of HR, with
646higher doses producing lower HRs when compared with
647control. A previous meta-regression has shown a similar
648effect when evaluating lower morphine consumption
649during the postoperative period.
8 These meta-regression
650results suggest that future studies should aim to use higher
651doses in order to improve the absolute effects of gabapentin
652on HR responses. Nevertheless, the oral route of
653gabapentin used in the included studies has implications
654for its use in high-risk patients, which may be prohibitive
655in emergency surgery. In addition, it is unclear whether
656titration of the gabapentin dosage would alter efficacy, an
657issue raised in the first POISE study.
4 Moreover, it is
658unclear whether such increases in dose would affect the
659incidence of bradycardia and hypotension, which may have
660been responsible for the increased mortality in POISE.
661With regard to the pharmacokinetics of gabapentin,
662bioavailability is known to decrease with increasing
663dosages, therefore plasma concentrations may not reflect
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664 the dose administered.
61 Baseline hemodynamic variables
665 recorded before induction were not associated with greater
666 attenuation of hemodynamic variables on meta-regression
667 analysis. This suggests that similar differences would be
668 achieved regardless of the baseline blood pressure or HR of
669 the participants. Despite this, it should be emphasized that
670 most of the included studies comprised low-risk non-
671 hypertensive patients, and therefore, the range of baseline
672 values was limited. Furthermore, our meta-regression
673 analysis may be underpowered to detect associations for
674 these outcomes.
675 Gabapentin was found to reduce the risk of hypertension
676 or tachycardia requiring treatment. This result is intuitive
677 given the observed effects of gabapentin on HR and blood
678 pressure. Nevertheless, data from the studies included in
679 this review are limited with regard to episodes of
680 bradycardia or hypotension. Indeed, one study in the
681 review excluded three patients from the analysis due to
682 hypotension,
47 and one study excluded a patient due to an
683 episode of bradycardia.
31 The former study was not
684 included in the meta-analysis as it did not report whether
685 these patients required treatment. As intraoperative
686 hypotension may be associated with stroke,
62 myocardial
687 injury, acute kidney injury,
63 and mortality,64 future studies
688 with gabapentin should aim to report these outcomes.
689 These studies should be well designed (with full intention-
690 to-treat analysis) and adequately powered to detect
691 differences in these clinically important outcomes and
692 avoid reporting surrogate outcomes such as hemodynamic
693 measurements. For example, we calculated a required
694 information size of 558 participants to provide a definitive
695 answer for our outcome of hypertension or tachycardia
696 (requiring treatment).
697 As previously stated, future research should aim to
698 report the incidences of adverse events associated with the
699 use of gabapentin in the perioperative period, particularly
700 as these may be associated with perioperative mortality.
701 This would have implications for the use of gabapentin for
702 attenuating the hemodynamic response to intubation as
703 well as for using it more widely in postoperative pain
704 control. Clinical trials should aim to address issues with
705 internal validity, such as the use of identical placebo
706 controls, intention-to-treat analysis of participants suffering
707 adverse events, and adequate allocation concealment.
708 Ultimately, adequately powered randomized-controlled
709 trials should examine the effects of gabapentin in high-
710 risk patients (such as those with previous myocardial
711 infarction or ischemic heart disease) and determine effects
712 on clinically relevant outcomes, such as mortality,
713 myocardial infarction, arrhythmia and myocardial
714 ischemia, while avoiding reporting surrogate variables as
715 primary outcomes.
716In conclusion, it remains unknown whether gabapentin
717improves clinically relevant outcomes such as death and
718myocardial infarction since studies failed to report on
719these. Nevertheless, this review has found evidence that
720gabapentin reduces HR and blood pressure responses to
721intubation. Even so, caution is advised with these results as
722there are few data from trials with a low risk of bias that
723focus on adverse hemodynamic events in high-risk
724patients. This novel meta-analysis shows the beneficial
725effects of gabapentin in attenuating the hemodynamic
726response to intubation.
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